



*This list of clinical research protocols relating to geriatric oncology is compiled for your convenience.*

*For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at [http://www.cancer.gov/clinical\\_trials](http://www.cancer.gov/clinical_trials).*

*A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.*

## SELECTED CLINICAL RESEARCH PROTOCOLS RELATING TO GERIATRIC ONCOLOGY

### Solid Tumors

**CLB-49907, CAN-NCIC-CLB-49907, CTSU, E-CLB-49907, SWOG-CLB-49907** Phase III Randomized Study of Adjuvant Chemotherapy Comprising Standard Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC) Versus Oral Capecitabine in Elderly Women With Operable Adenocarcinoma of the Breast

Chairperson: Hyman Bernard Muss, MD. Telephone: 802-847-3827; 800-358-1144. Lead organization: Cancer and Leukemia Group B. Age range: 65 and over.

**WSU-C-2305, AVENTIS-WSU-C-2305, NCI-V01-1687, WSU-06-15-01-M01-FB** Phase II Study of Celecoxib and Docetaxel as First-Line Therapy in Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer

Chairperson: Shirish Gadgeel, MD. Telephone: 313-745-8389; 800-527-6266. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: 18 and over.

**SWS-SAKK-25/99, EU-99007** Phase I/II Study of Capecitabine and Vinorelbine in Elderly Women With Metastatic Breast Cancer With or Without Bone Involvement

Chairperson: D. Hess, MD. Telephone: 071-494-1111. Lead organization: Swiss Institute for Applied Cancer Research. Age range: 65 and over.

**SWOG-S0030** Phase II Study of Capecitabine in Elderly Patients With Unresectable Metastatic or

### Recurrent Colorectal Cancer

Chairperson: Heinz-Josef Lenz, MD. Telephone: 323-865-3955; 1-800-872-2273. Lead organization: Southwest Oncology Group. Age range: 70 and over or 18 to 59.

**SWOG-S0029** Phase II Study of Docetaxel in Elderly Women With Metastatic Breast Cancer

Chairperson: Silvana Martino, DO. Telephone: 310-998-3961. Lead organization: Southwest Oncology Group. Age range: 70 and over or under 60.

### Myelodysplastic Syndromes

**EORTC-06011** Phase III Randomized Study of Low-Dose Decitabine Versus Standard Supportive Care in Elderly Patients With Myelodysplastic Syndromes

Chairperson: P.W. Wijermans, MD, PhD. Telephone: 31-070-359-2556. Lead organization: EORTC Leukemia Group. Age range: 60 and over.

### Acute Leukemia

**EORTC-06012, AML-17** Phase III Randomized Study of Standard Induction Chemotherapy With or Without Gemtuzumab Ozogamicin in Elderly Patients With Previously Untreated Acute Myeloid Leukemia

Chairperson: Sergio Amadori, MD. Telephone: 39-06-591-4745. Lead organization: EORTC Leukemia Group. Age range: 61 to 75.

**OSU-0164, NCI-4630** Phase I Study of Oblimersen, Cytarabine,

---

and Daunorubicin in Elderly Patients With Previously Untreated Acute Myeloid Leukemia

Chairperson: Guido Marcucci, MD. Telephone: 614-293-7597; 1-800-293-5066. Lead organization: Arthur G. James Cancer Hospital, Ohio State University. Age range: 60 and over.

**FHCRC-1654.00, NCI-H02-0094** Phase I/II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission

Chairperson: Brenda Sandmaier, MD. Telephone: 206-667-4961. Lead organization: Fred Hutchinson Cancer Research Center. Age range: 55 and over.

**SWOG-S0125** Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation With Pre-Conditioning Low-Dose Total Body Irradiation and Fludarabine Followed by Mycophenolate Mofetil and Cyclosporine in Elderly Patients With Acute Myeloid Leukemia in First Complete Remission

Chairperson: Peter McSweeney, MD. Telephone: 303-372-9000; 800-473-2288. Lead organization: Southwest Oncology Group. Age range: 55 to 69.

**SWOG-S0301** Phase II Study of Cyclosporine, Daunorubicin, and Cytarabine in Patients Age 56 and Over With Previously Untreated Acute Myeloid Leukemia

Chairperson: Thomas Chauncey, MD, PhD. Telephone: 206-764-2709. Lead organization: Southwest Oncology Group. Age range: 56 and over.

**NHLBI-01-H-0162, NCI-5783** Phase II Study of Selective T-Cell Depletion to Reduce Graft-Versus-Host Disease After Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Hematologic Malignancies

Chairperson: Scott Solomon, MD. Telephone: 301-496-5203. Lead organization: National Heart, Lung, and Blood Institute. Age range: 50 to 75.

**JJPRD-R115777-INT-21, UCLA-0209051** Phase II Study of Tipifarnib After Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia in First Complete Remission

Chairperson: Gary John Schiller, MD. Telephone: 310-825-5513. Lead organization: Jonsson Comprehensive Cancer Center, UCLA. Age range: 60 and over.

**E-3999** Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Zosuquidar Trihydrochloride in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB) in Transformation, or High-Risk RAEB

Chairperson: Larry Cripe, MD. Telephone: 317-274-3545; 1-888-600-4822. Lead organization: Eastern Cooperative Oncology Group. Age range: over 60.

**IRF-AML14, EU-20016** Phase III Randomized Study of Intensive Versus Nonintensive Chemotherapy in Older Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Chairperson: Alan K. Burnett,

MD, FRCP. Telephone: 44-029-20-742375. Lead organization: Leukemia Research Fund. Age range: 60 and over.

## Non-Hodgkin's Lymphoma

**EORTC-20991** Phase II/III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Versus Without Etoposide in Older Patients With Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin's Lymphoma

Chairperson: Pierre Soubeyran, MD. Telephone: 33-5-56-33-3267. Lead organization: EORTC Lymphoma Group. Age range: 70 and over.

**EORTC-20992** Phase II Study of Cyclophosphamide, Vincristine, and Prednisone in Frail Elderly Patients With Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin's Lymphoma

Chairperson: Pierre Soubeyran, MD. Telephone: 33-5-56-33-3267. Lead organization: EORTC Lymphoma Group. Age range: 70 and over.

**DSHNHL-1999-1A, EU-20243** Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Rituximab in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma

Chairperson: Michael G. M. Pfreundschuh, MD. Telephone: 49-6841-162-3002. Lead organization: German High-Grade Non-Hodgkin's Lymphoma Study Group. Age range: 61 to 80.